

**Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
March 13, 2006**

Meeting Participants

Consultants (voting), September 13, 2006

Session 1: Preclinical Study Design for Oncology Drug Products

Susan Bates, M.D.
Head, Molecular Therapeutics Section
National Institutes of Health
Medical Oncology Branch
Building 10, Room 12N226
10 Center Drive
Bethesda, MD 20892

Ralph D'Agostino, Ph.D.
Professor of Mathematics/Statistics
Boston University
Mathematics Department
111 Cummington Street
Boston, MA 02215

Tito Fojo, M.D., Ph.D.
Head, Experimental Therapeutics Section
National Institutes of Health
Medical Oncology Branch
Building 10, Room 12C103
10 Center Drive
Bethesda, MD 20892

Eric Kodish, MD
F. J. O'Neill Professor and Chair
Department of Bioethics - JJ60
Cleveland Clinic
9500 Euclid Avenue
Cleveland, OH 44195-0001

Chris H. Takimoto, MD, PhD, FACP
Director of Pharmacology
Zachry Chair of Translational Research
Institute for Drug Development
Cancer Therapy and Research Center
Alice P. McDermott Building
14960 Omicron Drive
San Antonio, TX 78245-3217

Patient Representative (voting)

Martha Solanche, New York

Guest Speakers (non-voting)

James Green, Ph.D.
Senior Vice President of Preclinical &
Clinical Development Sciences
Biogen Idec, Inc.
4 Kato Summit
Sudbury, MA 01776

**Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
March 13, 2006**

Meeting Participants Continued

Afternoon Session: Gemzar (gemcitabine hydrochloride), Eli Lilly & Co.

Ralph D'Agostino, Ph.D.
Professor of Mathematics/Statistics
Boston University
Mathematics Department
111 Cummington Street
Boston, MA 02215

Harry Long, M.D.
Associate Professor of Oncology
Mayo Clinic College of Medicine
Division of Medical Oncology
200 1st Street SW
Rochester, MN 55905-0001

Stacy Nerenstone, M.D.
Senior Physician &
Associate Clinical Professor
Department of Medicine
University of Connecticut
Hartford, CT 06106-2527

Patient Representative (voting):

Martha Solonche, New York